In a video interview with Pharma Commerce, Donald Prentiss, founder and CEO of Qualthera, describes how compounding pharmacies play a critical role in addressing unique and unmet medication needs that cannot be met by commercially available drugs. Their role in the pharmaceutical supply chain varies depending on the type of compounding facility: 503A or 503B.
A 503B facility, also known as an outsourcing facility, primarily supplies office-use medications to healthcare providers, who then administer them to patients. These facilities must adhere to current Good Manufacturing Practice (cGMP) standards, as they are FDA-registered and subject to inspections. In contrast, a 503A facility focuses on compounding medications based on individual prescriptions, typically in smaller, patient-specific batches. This allows for customization, such as removing allergens or adjusting dosage forms to better suit a patient’s needs.
Both types of compounding pharmacies are particularly useful in cases of drug shortages or when commercially available drugs are insufficient. For example, if a patient requires a medication that is in short supply, a compounding pharmacy can step in to provide a tailored solution. This flexibility makes compounding pharmacies essential for meeting the unique needs of patients, whether by modifying an existing medication or creating entirely new formulations to address specific medical conditions.
Ultimately, the primary function of compounding pharmacies is to bridge gaps in the pharmaceutical market by providing personalized, alternative treatments that meet the diverse needs of patients.
Prentiss also comments on the tirzepatide shortage, the notion that commercialized and compounded drugs are competing with one another, what needs to be done amid the various legal battles pertaining to GLP-1s that are currently taking place, and much more.
A transcript of his conversation with PC can be found below.
PC: Could you describe the importance of the patient within the pharma supply chain?
Prentiss: We’re here to serve the patient. They are our primary stakeholder. Whether there’s physicians involved, nurse practitioners, vendors, 503A’s, 503B’s. I just encourage everyone to remember that and bring it back home. At the end of the line, there’s going to be your family member, my family member, who will be affected by these medications, and we definitely do not want to have a repeat of what happened with the New England Compounding Center, which is widely known in industry. That is actually what gave birth to section 503B, which created outsourcing facilities just over 10 years ago. We don’t want more tragedy like that. Let’s just keep it focused on the patient, keep it focused on quality, and I think we’ll end up just fine.